sur Mainz BioMed N.V.
Mainz Biomed Releases 2024 Financial Results
Mainz Biomed N.V., a molecular genetics diagnostic company, reports a significant 33% increase in lab network revenue for 2024, driven by strong demand for its ColoAlert® test in Europe. Operating and net losses decreased by 30% and 18%, respectively, due to focused cost reductions and strategic initiatives.
The company established key partnerships, including collaborations with Thermo Fisher Scientific and Quest Diagnostics, enhancing their product development and reaching compliance with Nasdaq listing requirements. In 2024, Mainz Biomed achieved promising results from its studies, notably showcasing a 97% sensitivity for colorectal cancer at DDW 2024.
The company maintains a strategic focus on expanding ColoAlert® in Europe and developing next-gen screening technologies, aiming for FDA approval. Early 2025 advancements include the commencement of the eAArly DETECT 2 study and licensing agreement with Liquid Biosciences for pancreatic cancer detection.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Mainz BioMed N.V.